



Doernbecher
Children's Hospital

School of Medicine
Department of Pediatrics

3181 S.W. Sam Jackson Park Road
Mail Code: L321
Portland, OR 97239-3098
Tel 503.494.1210
Fax 503.418.5044
keller@ohsu.edu

Charles Keller, M.D.
Associate Professor
Leader, Pediatric Cancer Biology Program
Tarshis Professor of Pediatric Oncology
Pape' Family Pediatric Research Institute
Department of Pediatrics
Member, Knight Cancer Institute
Member, Oregon Stem Cell Center

November 02, 2011

Keith Desserich
Chairman – Board of Directors, The Cure Starts Now
10280 Chester Road, Cincinnati, Ohio 45215
Tel: (513)772-4888 www.thecurestartsnow.org

re: Project Proposal Funding Acknowledgement, *Rapid Preclinical Development of a Targeted Therapy Combination for DIPG*

Dear Keith,

My collaborators and I are grateful for the \$100,000 award from The Cure Starts Now circle of foundations for our above-named project. We are excited to get this project underway immediately, which addresses the goal our multi-national team and your foundation and supporters share of making DIPG a uniformly survivable cancer. Our team consists of the following laboratories:

myself & colleagues at the Oregon Health & Science University
Oren Becher MD, Duke University Medical Center
Michelle Monje MD, PhD, Stanford University
Maryam Fouladi MD, Cincinnati Children's Hospital Medical Center
Cynthia Hawkins, MD, PhD, University of Toronto
Xiao-Nan Li MD, PhD, Baylor College of Medicine

and through secondary support of \$20,000 each from the Lyla Nsouli Foundation and Accelerate Brain Cancer Cure:

Dannis G. van Vuurden MD, MSc, & Esther Hulleman, VU Cancer Center Amsterdam, and
Jacques Grill, Institut Gustave-Roussy, Villejuif, France

We are again thankful to The DIPG Symposium Collaboration, The Cure Starts Now Foundation, Reflections of Grace Foundation, The Jeffrey Thomas Hayden Foundation, Cancerfree Kids, Carly's Crusaders, The Max Lacewell Foundation, Smiles for Sophie Forever Foundation and Benny's World Foundation for making our project possible. In addition to our 6 month progress report, if at any point supporters wish to discuss study progress or visit our laboratory at OHSU, I can be reached at (503)494-1210 or keller@ohsu.edu.

Sincerely,



Charles Keller, M.D.

Co-Chair, Brain Tumor Developmental Therapeutics Committee (CNS-DVL)
Children's Oncology Group

and

Associate Professor
Leader, Pediatric Cancer Biology Program, Dept. of Pediatrics, OHSU

